Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naive Patients with HBeAg Positive Chronic Hepatitis B.
10.3346/jkms.2010.25.5.738
- Author:
In Hee KIM
1
;
Seok LEE
;
Seong Hun KIM
;
Sang Wook KIM
;
Seung Ok LEE
;
Soo Teik LEE
;
Dae Ghon KIM
;
Chang Soo CHOI
;
Haak Cheoul KIM
Author Information
1. Department of Internal Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Korea. daeghon@chonbuk.ac.kr
- Publication Type:Controlled Clinical Trial ; Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Hepatitis B, Chronic;
2'-fluoro-5-methylarabinosyluracil;
Lamivudine;
Virologic Breakthrough
- MeSH:
Adult;
Antiviral Agents/administration & dosage;
Arabinofuranosyluracil/administration & dosage/*analogs & derivatives;
Drug Resistance, Viral;
Female;
Hepatitis B e Antigens/*blood;
Hepatitis B, Chronic/diagnosis/*drug therapy/*immunology;
Humans;
Lamivudine/*administration & dosage;
Male;
Treatment Outcome
- From:Journal of Korean Medical Science
2010;25(5):738-745
- CountryRepublic of Korea
- Language:English
-
Abstract:
The authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naive patients with HBeAg positive chronic hepatitis B. In this retrospective study, a total of 116 HBeAg positive patients, who received 30 mg of clevudine once daily (n=53) or 100 mg of lamivudine once daily (n=63) for 48 weeks, were included. At week 48, clevudine therapy produced a significantly greater mean reductions in serum HBV DNA levels from baseline than lamivudine therapy (-5.2 vs. -4.2 log(10)IU/mL; P=0.005). Furthermore, a significantly higher proportion of patients on clevudine achieved negative serum HBV DNA by PCR (<13 IU/mL) at week 48 (60.4% vs. 38.1%; P=0.025). The incidence of virologic breakthrough in the clevudine group was significantly lower than in the lamivudine group (9.4% vs. 25.4%; P=0.031). However, rates of alanine aminotransferase normalization and HBeAg loss or seroconversion were similar in the two groups (83.0% vs. 81.0%, 11.3% vs. 11.1%; P=0.813, 1.000, respectively). In conclusion, clevudine is more potent for viral suppression and lower for antiviral resistance at week 48 than lamivudine in treatment of naive patients with HBeAg positive chronic hepatitis B.
